OVERVIEW OF ACTIVITY

It is important for the practicing oncologist to be aware of similarities and differences between his or her practice patterns, those of others in community practice and those of lung cancer clinical investigators. It is also important for oncologists to recognize that heterogeneity exists in the oncology community, especially in clinical situations for which there is suboptimal research evidence.

This program focuses on the self-described practice patterns of randomly selected medical oncologists on a variety of key clinical issues in cancer. Also included are clinical investigator commentary and references addressing these issues. This CME program will provide medical oncologists with information on national cancer patterns of care to assist with the development of clinical management strategies.

LEARNING OBJECTIVES

• Compare management strategies of community oncologists and cancer clinical investigators in the localized, locally advanced and metastatic settings, and utilize this information to develop practical lung cancer treatment algorithms.
• Identify clinical scenarios for which relative agreement and heterogeneity exist in patterns of care for lung cancer, and apply these findings to the individualized treatment of patients.
• Counsel patients with lung cancer about the benefits and risks of multiple acceptable treatment options when they exist.
• Recognize the rate with which practice-changing clinical research impacts oncologist decision-making, and explain how this affects patient access to standard and novel therapeutics.
• Recall the design and eligibility criteria for ongoing lung cancer clinical trials and consider appropriate patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

To receive credit for this activity, the participant should review the CME information, read the monograph and complete the Educational Assessment and Credit Form located on our website at www.ResearchToPractice.com/POC/Lung. PowerPoint files of the graphics contained in this document can be downloaded at www. ResearchToPractice.com/POC/Lung.

COMMERCIAL SUPPORT

This program is supported by educational grants from Genentech BioOncology/OSI Oncology and Sanofi-Aventis.

PHARMACEUTICAL AGENTS DISCUSSED IN THIS PROGRAM

This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Miller — Advisory Board: Abraxis BioScience, Bayer Pharmaceuticals Corporation, Eli Lilly and Company, ImClone Systems Incorporated; Advisory Committee: Exelixis Inc, Genentech BioOncology, OSI Oncology; Consulting Agreements: Abbott Laboratories, Boehringer Ingelheim GmbH.

EDITOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

CME DISCLOSURES FOR QUOTED FACULTY

Dr Kris had no financial interests or affiliations to disclose. Dr Bonomi — Advisory Committee: Eli Lilly and Company, ImClone Systems Incorporated, OSI Oncology; Consulting Agreements and Speakers Bureau: Eli Lilly and Company; Paid Research: Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems Incorporated, Novartis Pharmaceuticals Corporation, OSI Oncology, Pfizer Inc. Dr Brahmer — Consulting Agreements: Cephalon Inc, Eli Lilly and Company, Genentech BioOncology; Paid Research: AstraZeneca Pharmaceuticals LP, Merck and Company Inc, Medarex Inc, Pfizer Inc, Wyeth. Dr Bunn — Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems Incorporated, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis. Dr Curran — Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genmab, ImClone Systems Incorporated, OSI Oncology. Dr Edelman — Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company, Human Genome Sciences, Telik Inc; Contracted Research: Bristol-Myers Squibb Company. Dr Ettinger — Advisory Committee: Bristol-Myers Squibb Company, Eisai Inc, Eli Lilly and Company, GlaxoSmithKline, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Eli Lilly and Company, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Sanofi-Aventis; Paid Research: Genentech BioOncology, Pharmion Corporation; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Eli Lilly and Company, GlaxoSmithKline, Merck and Company Inc, Sanofi-Aventis; Stock Ownership: Eisai Inc, GlaxoSmithKline. Dr Greco — Advisory Committee: Bristol-Myers Squibb Company, Eli Lilly and Company; Paid Research: Eli Lilly and Company; Speakers Bureau: Eli Lilly and Company, GlaxoSmithKline. Dr Hanna — Consulting Fees: Bayer Pharmaceuticals Corporation, Eli Lilly and Company; Contracted Research: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Onyx Pharmaceuticals Inc. Dr Herbst — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Pfizer Inc, Sanofi-Aventis; Paid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Sanofi-Aventis. Dr Jablons — Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, OSI Oncology. Dr Johnson — Consulting Fees: Genzyme Corporation; Royalty: Patent EGFR Testing. Dr Lilenbaum — Consulting Agreement: Genentech BioOncology. Dr Lynch — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, ImClone Systems Incorporated, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis; Patent for EGFR Testing: Genzyme Corporation. Dr Natale — Advisory Committee: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, Pharmion Corporation, Roche Laboratories Inc; Consulting Agreements: Eli Lilly and Company; Paid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Millennium Pharmaceuticals Inc, Pfizer Inc, Pharmion Corporation, Sanofi-Aventis; Speakers Bureau: Genentech BioOncology, OSI Oncology. Dr Perez-Soler — Consulting Fees, Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents and Ownership Interest: Eli Lilly and Company, Genentech BioOncology; Receipt of Intellectual Property Rights/Patent Holder: Hana Biosciences Inc. Prof Pirker — Advisory Committee: Amgen Inc; Speakers Bureau: Amgen Inc, Eli Lilly and Company, Roche Laboratories Inc. Dr Riely — Consulting Agreements: Boehringer Ingelheim GmbH, Roche Laboratories Inc. Dr Sandler — Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, GlaxoSmithKline, Pfizer Inc; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, OSI Oncology, Pfizer Inc; Speakers Bureau: Eli Lilly and Company, Genentech BioOncology. Dr Socinski — Contracted Research: Abraxis BioScience, Genentech BioOncology, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Abraxis BioScience, Genentech BioOncology, Sanofi-Aventis. Dr Wakelee — Consulting Fees: Sanofi-Aventis; Other (Research Funding): Eli Lilly and Company, Genentech BioOncology. Dr Wozniak — Consulting Fees: AstraZeneca Pharmaceuticals LP, Sanofi-Aventis; Contracted Research and Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Eli Lilly and Company, Genentech BioOncology.

Click on the image to enlarge